September 6th 2024
There are remaining gaps in papillary renal cell carcinoma that data from 3 pending trials hope to fill.
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Ornstein Discusses TKI Dose Interruption and Discontinuation in Combination RCC Therapy
August 19th 2024During a Case-Based Roundtable® event, Moshe Ornstein, MD, MA, discussed dose modification approaches for patients receiving combination immunotherapy/tyrosine kinase inhibitor therapy for advanced renal cell carcinoma.
Read More
Motzer Examines Impact of IO/TKI Combination Trials for Non–Clear Cell RCC
August 13th 2024During a Case-Based Roundtable® event, Robert J. Motzer, MD, evaluated the available data for cabozantinib plus nivolumab and lenvatinib plus pembrolizumab as combination therapies for non–clear cell renal cell carcinoma.
Read More
George Explores Impact of Risk Status With Cabozantinib/Nivolumab in Advanced RCC
July 19th 2024During a Case-Based Roundtable® event, Daniel George, MD, discussed the results of the CheckMate 9ER trial across favorable, intermediate, and poor risk groups in patients with advanced renal cell carcinoma.
Read More
Review of CLEAR and CheckMate-9ER: Four-Year and 55 Month Follow-Up Data
July 3rd 2024Matthew Campbell, MD, MS, analyzes the crucial efficacy and safety results from the CLEAR trial's 4-year final analysis, incorporating insights on how these findings influence clinical decision-making for treatment-naïve patients with advanced renal cell carcinoma.
Watch
Review of CheckMate-214: Long-term follow-up in favorable risk subgroup
July 3rd 2024Rana McKay, MD, examines the pivotal efficacy and safety outcomes from the 8-year follow-up of the CheckMate-214 trial in treatment-naïve patients, presented at ASCO GU 2024, and discusses how these findings impact clinical practice.
Watch
Kilari Discusses Frontline Treatment Selection Factors for mRCC
June 27th 2024During a Case-Based Roundtable® event, Deepak Kilari, MD, discussed with participants how updated data on frontline regimens affects their choice of therapy for patients with metastatic clear cell renal cell carcinoma.
Read More
Patient Considerations for Using Dual Immunotherapy for RCC
June 26th 2024During a Case-Based Roundtable® event, Nizar M. Tannir, MD, discussed the importance of site of metastasis and other factors in the use of nivolumab plus ipilimumab in renal cell carcinoma in the first article of a 2-part series.
Read More
Current treatment options for ccRCC based on patient and disease factors
June 26th 2024Matthew Campbell, MD, MS, and Rana McKay, MD, offer a concise review of existing treatment approaches for clear cell renal cell carcinoma across risk categories, along with considerations for sequencing therapies.
Watch
The Field of Recurrent RCC Regimens Continues to Grow
June 12th 2024During a Case-Based Roundtable® event, Sumanta Kumar Pal, MD, discussed regimens for recurrent metastatic clear cell renal cell carcinoma including lenvatinib plus everolimus, belzutifan, and investigational cell therapy and bispecific agents in the second article of a 2-part series.
Read More
Clinical Benefit Seen With Lenvatinib/Pembrolizumab in ccRCC, Irrespective of Biomarker Subtypes
June 3rd 2024Lenvatinib in combination with pembrolizumab yielded a greater clinical benefit rate compared with sunitinib in advanced clear cell renal cell carcinoma, regardless of patient biomarker subtype.
Read More